From: Does glycemic control reverse dispersion of ventricular repolarization in type 2 diabetes?
 | Type 2 diabetes | Control | P |
---|---|---|---|
 | (n = 44) | (n = 44) |  |
Clinical variables | Â | Â | Â |
Age (years) | 60.6 ± 13.8 | 58.4 ± 11.4 | 0.353 |
Male | 24 (54.5%) | 22 (50.0%) | 0.674 |
BMI (kg/m2) | 26.7 ± 4.4 | 22.6 ± 2.8 | <0.001 |
SBP (mmHg) | 124.8 ± 16.8 | 118.3 ± 13.4 | 0.048 |
DBP (mmHg) | 74.2 ± 9.4 | 71.6 ± 9.7 | 0.204 |
Smoking | 24 (54.5%) | 20 (45.5%) | 0.400 |
Duration of DM (years) | 12.5 ± 12.0 | N/A |  |
Retinopathy | 14 (31.8%) | N/A | Â |
Nephropathy | 18 (40.9%) | N/A | Â |
Autonomic neuropathy | 7 (15.9%) | N/A | Â |
CAD | 9 (20.5%) | N/A | Â |
Laboratory variables | Â | Â | Â |
FPG (mg/dl) | 170.3 ± 49.5 | 89.7 ± 8.0 | <0.001 |
HbA1c (%) | 10.0 ± 1.6 | 5.6 ± 0.3 | <0.001 |
Triglyceride (mg/dl) | 228.1 ± 246.0 | 88.2 ± 38.9 | <0.001 |
HDL-C (mg/dl) | 44.5 ± 12.4 | 54.8 ± 10.2 | <0.001 |
LDL-C (mg/dl) | 115.9 ± 40.0 | 129.4 ± 27.4 | 0.0069 |
Creatinine (mg/dl) | 0.66 ± 0.22 | 0.64 ± 0.14 | 0.597 |
Uric acid (mg/dl) | 5.0 ± 1.4 | 5.1 ± 1.4 | 0.596 |
Potassium (mEq/l) | 4.1 ± 0.4 | 4.3 ± 0.1 | 0.074 |
Medications | Â | Â | Â |
ACE-I/ARB | 16 (36.4%) | N/A | Â |
CCB | 13 (29.5%) | N/A | Â |
β blocker | 5 (11.4%) | N/A |  |
Other antihypertensive drugs | 8 (18.2%) | N/A | Â |
Sulphonylurea | 19 (43.2%) | N/A | Â |
α-glucosidase inhibitor | 19 (43.2%) | N/A |  |
Biguanide | 16 (36.4%) | N/A | Â |
DPP-4 inhibitor | 14 (31.8%) | N/A | Â |
Insulin | 8 (18.2%) | N/A | Â |
Other antidiabetic drugs | 6 (13.6%) | N/A | Â |
Statin | 14 (31.8%) | N/A | Â |
Fibrate | 2 (4.5%) | N/A | Â |
Electrocardiographic variables | Â | Â | Â |
Heart rate (bpm) | 74.2 ± 15.5 | 61.0 ± 8.6 | <0.001 |
V1S + V5R (mV) | 2.37 ± 0.58 | 2.14 ± 0.68 | 0.093 |
QTc mean (ms) | 413.6 ± 18.5 | 408.3 ± 22.7 | 0.229 |
QT dispersion (ms) | 41.8 ± 15.4 | 28.7 ± 7.7 | <0.001 |
QTc dispersion (ms) | 45.9 ± 16.3 | 28.8 ± 7.3 | <0.001 |
Tpeak-Tend in V5 (ms) | 83.6 ± 13.6 | 71.3 ± 10.3 | <0.001 |